Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. - Wikidata - awgldk - TriplyDB

Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

http://www.wikidata.org/entity/Q35235743

about

PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines PLK1, A Potential Target for Cancer Therapy Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay Therapeutic Implications of Black Seed and Its Constituent Thymoquinone in the Prevention of Cancer through Inactivation and Activation of Molecular Pathways.Function of survivin in trophoblastic cells of the placenta.Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition Mitotic centromere-associated kinesin (MCAK): a potential cancer drug target.Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.Kizuna is a novel mitotic substrate for CDC25B phosphatase Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain Cdk1 and Plk1 mediate a CLASP2 phospho-switch that stabilizes kinetochore-microtubule attachments Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy B-cell lymphoma 6 promotes proliferation and survival of trophoblastic cells Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.Polo-like kinase-1 in DNA damage response.Current assessment of polo-like kinases as anti-tumor drug targets.Understanding the Polo Kinase machine.The role of Plk3 in oncogenesis.Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.Polo-like kinase 1 regulates the stability of the mitotic centromere-associated kinesin in mitosis.pERK 1/2 inhibit Caspase-8 induced apoptosis in cancer cells by phosphorylating it in a cell cycle specific manner.p21Waf1/Cip1 deficiency causes multiple mitotic defects in tumor cells.Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.The activity regulation of the mitotic centromere-associated kinesin by Polo-like kinase 1 Polo-like kinase 1 as target for cancer therapy.Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.Polo-like kinases in AML.Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators.Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.Upregulation of C/EBPα contributes to colorectal cancer growth, metastasis and indicates poor survival outcome

P2860

Q26777811-68855EA9-EBF1-47F3-A015-524619A8981F Q27334288-97EB6404-4193-494F-BFEF-F62E7576295A Q28078772-4727D37E-5C37-41C6-9A19-154D01731E18 Q28552326-47A90FA6-1D99-44E5-8943-A3E0FC8F3F42 Q28820936-109C993D-4703-434E-8216-1B81E1A78242 Q33736242-F08F1096-9C54-44D1-82E7-2289825682A0 Q34998646-DF844B59-19A7-46E8-ADB6-D640DE6E96D6 Q35740037-453CAD75-D9B9-4925-A62A-44C73816E89D Q35764416-53039A68-D304-4D42-8DB6-D766BF74BE4D Q35801683-B4D0FCF2-981B-4F08-BFF0-E2CBD4330512 Q35867866-F07D39DA-68AB-42E9-8E65-B2BCA452E772 Q36189477-14663C18-66B4-4D83-AF53-997D3DBB2082 Q36207913-169EBB0C-C454-40A0-9B73-FAE30E70DF23 Q36317230-183D2A8C-EBAF-4754-B757-83B51FE3DD9D Q36386336-CC21A58B-21FF-414B-8919-7AA2418B5B07 Q36839342-752A14C9-77F9-4C6B-B79D-A8300F66F789 Q37708943-7B9F8BE4-4C9C-4481-B019-E7BF81B47C0C Q38129174-A87EE90C-E92E-4A1C-8F5C-3A85D6F790D2 Q38199282-2ADE4E18-05A7-4CFF-B520-B1D078C3DF25 Q38211244-7E673189-633C-43A6-946C-38339DFCC355 Q38331761-A61B15BE-0F62-4E3F-BAAC-B6F166F96A34 Q38444150-9CF19240-1354-4328-99C5-31E5060A991D Q38872725-F24EC514-2B74-4497-90E4-F4467E73E36D Q38961886-C9F48B8E-1DB3-41FE-AE3B-2447C8981B25 Q38984499-060CEFF5-2C30-48F7-94A6-4A9F20BC1868 Q39042925-3549C785-2737-4ECD-BB03-652CEF17961A Q39045570-455DBFCF-C464-43FC-A5CB-65B6A5B0C0AB Q41461306-F737CFFF-528D-48CF-83CF-DBDEF5A0492F Q41694208-82F9E3D3-831A-41B7-9935-B768448B78DF Q41813783-83EA8609-E128-4B1E-BD27-1530377DD660 Q41866750-4B316E72-8B5C-4788-9CCE-4144F7442CE7 Q50939437-01ED49FD-C276-4E82-8AEC-765ADD2CEAED Q50994164-7DC6270D-5E4B-4634-B046-93EA14BB4885 Q53000908-8C02ABB6-482B-4668-9CDF-0F659BE3532B Q53015871-DC7473DD-8A7E-4800-B4D8-026B5967CD72 Q58804585-EEAA0E33-E187-4627-A530-D2A745A2AC8E

P2860

Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

http://www.wikidata.org/entity/Q35235743

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.

@ast

Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.

@en

type

label

Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.

@ast

Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.

@en

prefLabel

Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.

@ast

Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.

@en

P1433

Q35235743-508991CE-9932-4E62-9221-ED57194A77DB

P1476

Q35235743-0079797B-0A2D-47BA-8A24-033980781F67

P2093

Q35235743-2FA66FE8-9648-4E28-8431-4B00F1613843

Q35235743-376E9D55-6AE0-46C6-B876-55D7EC302FEB

Q35235743-5087278E-3502-4708-9ABF-659A23502742

Q35235743-5EC96CEB-0EB0-4C0A-AE8F-E6028C4CF272

Q35235743-7447E860-209F-46DE-BC77-E1F21BC26B99

Q35235743-9F5273C8-1182-479B-AB95-CCE2FCA3615A

Q35235743-BAA46F3F-B240-425A-9679-D7F7AE2F1AB8

Q35235743-C6A61232-3BB8-4086-BE60-020D1D8F3D1B

Q35235743-CA1200E7-416C-48A9-9011-FC5FA0FD4531

P2860

Q35235743-03CF8AB9-0F5F-4B02-BE98-1724BA367342

Q35235743-059D4C48-FAE0-428A-A46B-2944B8DE8976

Q35235743-08D5BACA-ED7B-43D3-8A56-780A67AFDDF1

Q35235743-162483AB-D799-4E9D-8CB0-B574BA400F9E

Q35235743-2A166A48-ED28-4859-B0D1-1B721FDD2E03

Q35235743-2C0F12AB-0688-4D13-9E67-DEBD1CE8689B

Q35235743-2C9F5AE2-1909-4DE4-86A0-7C8CC6E723EB

Q35235743-3823494B-1532-400C-B339-ECE1B8387E9E

Q35235743-3979030E-BD7D-4A6F-96EE-F6BD5D40D02F

Q35235743-3C975763-EF42-4ACE-8DEC-93E6853E5B53

P304

Q35235743-7CE5050B-C744-4466-A6F8-C2DB919E3058

P31

Q35235743-DC17E3F6-48AF-42D2-A6AF-CB498241973B

P356

Q35235743-2F439260-A37B-462D-927F-38708FA13DEC

P407

Q35235743-7FCB8248-AA57-4811-95D9-25AF5A2A13D2

P433

Q35235743-1715D103-20CD-4BF3-BAC3-D6489926B95F

P478

Q35235743-B7803F4F-4150-49E4-850A-4AECB90787F4

P577

Q35235743-747BAADF-2B05-4171-A930-62715BB3871E

P5875

Q35235743-4F9C8449-D1FF-42C3-87EE-67F66095EF18

P698

Q35235743-7C2DAEBB-C44C-488B-BBAF-F3F438179D88

P932

Q35235743-194CEE49-AB79-47AA-B091-A005370194DE

P356

J.AJPATH.2011.06.031

P1433

The American Journal of Pathology

P1476

Polo-box domain inhibitor polo ...... inhibits tumor growth in vivo.

@en

P2093

Andrea Krämer

http://www.w3.org/2001/XMLSchema#string

Brigitte Zimmer

http://www.w3.org/2001/XMLSchema#string

Juping Yuan

http://www.w3.org/2001/XMLSchema#string

Klaus Strebhardt

http://www.w3.org/2001/XMLSchema#string

Matthias Hofmann

http://www.w3.org/2001/XMLSchema#string

Mourad Sanhaji

http://www.w3.org/2001/XMLSchema#string

Nina-Naomi Kreis

http://www.w3.org/2001/XMLSchema#string

Thorsten Berg

http://www.w3.org/2001/XMLSchema#string

Wolfgang Reindl

http://www.w3.org/2001/XMLSchema#string

P2860

The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus

The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity

sSgo1, a major splice variant of Sgo1, functions in centriole cohesion where it is regulated by Plk1

Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes

Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression

Association of polo-like kinase with alpha-, beta- and gamma-tubulins in a stable complex

Plk phosphorylation regulates the microtubule-stabilizing protein TCTP.

Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1

Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function

Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

P304

2091-2099

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJPATH.2011.06.031

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51568969

http://www.w3.org/2001/XMLSchema#string

P698

21839059

http://www.w3.org/2001/XMLSchema#string

P932

3181368

http://www.w3.org/2001/XMLSchema#string